# Colin Walsh

> Colin Walsh is a Series B investor at Goldman Sachs backing Biotechnology and Health Care. See 13 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Goldman Sachs](https://shizune.co/investors/profile/goldman-sachs)
- Location: San Francisco, United States
- Total investments: 13
- Last investment: Jan 2026
- Lead investor: 54%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/colinlwalsh/
- Website: https://x.com/colinlwalsh
- Facebook: https://www.facebook.com/colin.walsh.3745

Colin Walsh is a Series B investor at Goldman Sachs in San Francisco focused on Biotechnology and Health Care. Colin Walsh is based out of Alachua, Florida and is the Managing Director of Life Sciences of Goldman Sachs Alternatives and Board of Director of Beacon Therapeutics. Colin previously worked at Qiming Venture Partners USA as a Partner. Colin Walsh attended the University of Massachusetts, Amherst.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 62% |
| Health Care | 7 | 54% |
| Medical | 5 | 38% |
| Life Science | 3 | 23% |
| Therapeutics | 3 | 23% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 31% |
| Series A | 3 | 23% |
| Series C | 2 | 15% |
| Funding Round | 2 | 15% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 54% |
| United Kingdom | 2 | 15% |
| Canada | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AirNexis Therapeutics | AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions. | $200M | Series A | Jan 09, 2026 |  |
| AirNexis Therapeutics | AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions. | $200M | Series A | Jan 09, 2026 |  |
| Attovia Therapeutics | Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated. | $90M | Series C | Apr 15, 2025 |  |
| Vicebio | Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses. Vicebio is a biopharmaceutical business that creates innovative vaccinations to prevent potentially fatal respiratory viral infections. | $100M | Series B | Sep 23, 2024 |  |
| Attovia Therapeutics | Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated. | $105M | Series B | May 09, 2024 |  |
| Abdera Therapeutics | Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs. | $142M | Series B | Apr 20, 2023 |  |
| Entact Bio | Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins. | $81M | Series A | Dec 06, 2022 |  |
| Ceptur Therapeutics | Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company’s wholly owned and proprietary U1 Adaptor technology promotes non-genotoxic and long-lasting silencing of disease-causing genes in difficult to target tissues (i.e., outside of the liver and CNS). | $75M | Series A | Jan 19, 2022 |  |
| Emulate | Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. | $17M | Series B | Oct 20, 2016 |  |
| Pulse Therapeutics | Pulse Therapeutics is a growing medical technology company headquartered in St. Louis, Mo. The medical developer is advancing the fight against stroke, heart disease, and other conditions with its high-level treatment solutions, which utilize the latest biomedical technology and processes.Pulse’s signature offering, the MED System, was designedto harness magnet-based technology to rapidly dissolve blood clots faster than current modalities. This faster rate of delivery of FDA-approved clot-busting medication could dramatically reduce the number of lives lost each year to stroke, heart disease, and other diseases.This pioneering medical development company was founded by leading physicists Francis “Duke” Creighton and Rogers Ritter. Dr. Creighton, who also serves as Pulse’s chief technical officer, has 20-plus years of expertise in the medical technology industry, specializing in the stroke and cardiovascular sectors. He responsible for 30 patents and is a technology reviewer for the National Cancer Institute, National Science Foundation, and National Institutes of Health.The ground-breaking medical solutions of Pulse Therapeutics continues to attract investors and garner media coverage. | $10M |  | Jan 27, 2016 |  |

10 of 13 investments shown.

## Co-investors
- [venBio Partners](https://shizune.co/investors/profile/venbio) — VC Fund, 6 deals together
- [Frazier Life Sciences](https://shizune.co/investors/profile/frazier-life-sciences) — VC Fund, 4 deals together
- [Cultivation Capital](https://shizune.co/investors/profile/cultivation-capital) — VC Fund, 2 deals together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 2 deals together
- [Enavate Sciences](https://shizune.co/investors/profile/enavate-sciences) — VC Fund, 2 deals together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 2 deals together

## About Goldman Sachs

VC Fund · New York, United States

The Goldman Sachs Group, Inc. provides investment banking, securities, and investment management services, as well as financial services to corporations, financial institutions, governments, and high-net-worth individuals worldwide.Its Investment Banking segment offers financial advisory services, including advisory assignments concerning mergersand acquisitions, divestitures, corporate defense, risk management, and restructurings and spin-offs; and underwriting services comprising public offerings and private placements of a range of securities, loans, and other financial instruments, and derivative transactions.The company’s Institutional Client Services segment provides client execution services, such as fixed income, currency, and commodities client execution related to making markets in interest rate products, credit products, mortgages, currencies, and commodities; and equities related to making markets in equity products, as well as executes and clears institutional client transactions on stock, options, and futures exchanges.This segment also engages in the securities services business providing financing, securities lending, and other brokerage services to institutional clients, including hedge funds, mutual funds, pension funds, and foundations. Its Investing and Lending segment originates longer-term loans; and invests in debt securities, loans, public and private equity securities, real estate, consolidated investment entities, distressed assets, currencies, commodities, and power generation facilities.The company’s investment management segment provides investment products and services, as well as offers wealth advisory services, including portfolio management and financial counseling, and brokerage and other transaction services.

5 contacts available at Goldman Sachs.

| Name | Title | Profile |
| --- | --- | --- |
| Christopher Dawe | Co-Head Private Investments | https://shizune.co/investors/profile/christopher-dawe |
| Colin Walsh | Managing Director of Life Sciences Investing | https://shizune.co/investors/profile/colin-walsh-4 |
| David Solomon | Chief Executive Officer | https://shizune.co/investors/profile/david-m-solomon |
| Hillel Moerman | Co-Head Private Capital Group | https://shizune.co/investors/profile/hillel-moerman |
| James Hayward | Managing Director | https://shizune.co/investors/profile/james-hayward-022e |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Colin Walsh invest in?

Colin Walsh invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Colin Walsh last invest?

The most recent investment recorded for Colin Walsh closed in Jan 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co